It wasn’t supposed to happen like this. The expectation was that the new PAMA market-based pricing system was going to save Medicare 10 percent or more on lab test reimbursements. But it hasn’t happened, at least not in 2018, the first year under the PAMA scheme. That’s the surprising conclusion of a new OIG report…
OIG Reports that 2018 Medicare Part B Lab Test Spending Increased Despite PAMA Cuts
It wasn’t supposed to happen like this. The expectation was that the new PAMA market-based pricing system was going to save Medicare 10 percent or more on lab test reimbursements. But it hasn’t happened, at least not in 2018, the first year under the PAMA scheme. That’s the surprising conclusion of a new OIG report […]